FDA's Risk-Based Inspection Shift: What It Actually Rewards

For years, the safest way to prepare for an FDA pre-approval inspection was to assume it was coming and over-prepare accordingly. That assumption is getting more expensive to make. FDA has revised Compliance Program 7346.832, "Preapproval Inspections," reinforcing a risk-based approach to deciding whether a PAI happens at all, and the revised program takes effect August 10, 2026, replacing the version that had been in place since October 2022.

The device side of the business has already lived through a version of this shift. Since the Quality Management System Regulation (QMSR) became effective February 2, 2026, FDA replaced the old Quality System Inspection Technique (QSIT) with a new risk-based inspection approach under Compliance Program 7382.850, applied across preapproval, for-cause, and routine post-market device inspections. Under that model, Class I device manufacturers generally do not face routine inspection unless a for-cause trigger or health-hazard signal exists. The drug-side PAI revision extends the same underlying logic: inspection resources go where the risk assessment says they are needed, not everywhere by default.

What actually changed

The revised compliance program formalizes a holistic, risk-based determination process. When a marketing application comes in, an Integrated Quality Assessment (IQA) team assembles to evaluate the facilities named in it, weighing factors like inspection history, the specific risks tied to the product and its manufacturing process, and prior compliance signals, before deciding whether an onsite inspection is warranted at all.

Where FDA decides an onsite inspection is not necessary, the guide clarifies the alternative tools available:

• Requesting existing inspection reports and other information from trusted foreign regulatory partners through Mutual Recognition Agreements and similar confidentiality agreements.
• Conducting remote regulatory assessments, including direct record requests from the facility and remote interactive evaluations in place of a site visit.

The revised program also adds a flow diagram that lays out, step by step, how the risk-based determination gets made. That is a meaningful change in itself: it turns what used to feel like an opaque internal judgment call into a documented decision path manufacturers can actually prepare against.

Why this rewards continuous readiness over one-time prep

A risk-based model does not reward the facility that assembles a war room three weeks before a scheduled inspection. It rewards the facility whose inspection history, compliance signals, and documentation are already clean on the day FDA runs its risk assessment, because that assessment can happen with little warning and without an announced visit.

That is a hard model to serve with a manual, consultant-driven prep cycle. A spreadsheet-based readiness effort or a pre-inspection audit sprint can get a facility ready for a known date. It cannot keep that facility continuously ready for a risk score FDA calculates on its own schedule, using inspection history the facility does not fully control. Scaling that kind of standing readiness with headcount and outside consultants gets expensive fast, and it does not compound. Scaling it with a system that keeps documentation, CAPA history, and compliance signals continuously mapped and audit-ready does.

What to check now

1. Review your CAPA and complaint-handling history for the kind of gaps FDA's fiscal year inspection data continues to flag most often, since those remain the fastest way to trigger a for-cause look regardless of the risk model in place.
2. If you manufacture in multiple jurisdictions, confirm whether a Mutual Recognition Agreement between FDA and your local regulator could reduce your onsite inspection exposure, and make sure your documentation is ready to support a remote assessment if one is requested instead.
3. Treat "risk-based" as a standing requirement, not a pre-inspection sprint. The IQA team's assessment can happen before you know it is happening.

For background on how 21 CFR 820 violations turn into inspection findings and warning letters, see Qualio's 21 CFR Part 820: the complete overview and how to respond to FDA warning letters. For the QMSR-specific inspection shift, see what is the FDA QMSR. For the source material on this revision, see RAPS' coverage of the revised PAI compliance guide and FDA's Compliance Program 7346.832 itself.

If your inspection readiness still depends on a pre-audit scramble, see how continuous, audit-ready documentation removes that dependency.